Granzyme B inhib 
Welcome,         Profile    Billing    Logout  
 0 Companies  0 Products   0 Products   0 Diseases   0 Trials   0 News 


«12...56789101112131415...2627»
  • ||||||||||  Journal:  Fish Granzyme A Shows a Greater Role Than Granzyme B in Fish Innate Cell-Mediated Cytotoxicity. (Pubmed Central) -  Oct 22, 2020   
    However, the immunohistochemistry study revealed an increased number of GzmB stained cells and areas in the brain of seabream after NNV infection, which was mainly associated with the lesions detected. Further studies are needed to ascertain the molecular nature, biological function and implication of fish granzymes in the CMC activity, and in the antiviral defense in particular.
  • ||||||||||  Clinical, Journal:  Circulating Mucosal-Associated Invariant T Cells in a Large Cohort of Healthy Chinese Individuals From Newborn to Elderly. (Pubmed Central) -  Oct 16, 2020   
    Upon in vitro activation with PMA plus ionomycin or IL12 plus IL18, fewer MAIT cells isolated from the young adult group expressed IFN-γ, IL17A and Granzyme B then cells from other age groups while the proportion of cells that expressed TNF-α was similar. Taken together, our data provide information for guiding the assessment of normal levels and phenotypes of MAIT cells at different ages in healthy individuals and patients.
  • ||||||||||  zoledronic acid / Generic mfg.
    Journal:  Regulatory Interactions Between Neutrophils, Tumor Cells and T Cells. (Pubmed Central) -  Oct 16, 2020   
    We have previously shown that zoledronic acid (ZOL)-activated neutrophils inhibit γδ T-cell proliferation due to the production of reactive oxygen species, arginase-1 and serine proteases...Our present results demonstrate that the presence of neutrophils can enhance the killing capacity of activated γδ T cells. We discuss these results in the broader context of regulatory interactions between neutrophils and T lymphocytes.
  • ||||||||||  Journal, PD(L)-1 Biomarker, IO Biomarker:  Mass Cytometry Discovers Two Discrete Subsets of CD39Treg Which Discriminate MGUS From Multiple Myeloma. (Pubmed Central) -  Oct 16, 2020   
    In conclusion, the use of mass cytometry and FlowSOM clustering discovered two discrete subsets of CD39Treg which are discordant in MGUS and NDMM patients and may be permissive of myeloma growth which warrants further study. Understanding the regulatory properties of these subsets may also advance MGUS and MM diagnosis, prognosis, and therapeutic implications for MM patients.
  • ||||||||||  [VIRTUAL] Myeloid Cell Infiltration Correlates with Prognosis and Varies Based on Tumor Location in Cholangiocarcinoma () -  Oct 14, 2020 - Abstract #SITC2020SITC_1771;    
    D-ECC has a favorable immune profile compared to ICC and H-ECC, with a better milieu for antigen presentation including increased mesothelin and less suppressive macrophages, which may support better response to checkpoint blockade. The data supported the hypothesis that higher densities of intra-tumoral M2 macrophages and myeloid cells correlated with worse OS, even after controlling for clinical variables, suggesting that these cell populations may represent promising immunotherapeutic targets in CC.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Oxygen concentration alters Natural Killer cell phenotype and function in the solid tumor microenvironment () -  Oct 14, 2020 - Abstract #SITC2020SITC_1698;    
    At the end of the incubation period NK cells were counted and plated at a 2:1 E:T ratio with fluorescently labeled K562 targets or fluorescently labeled labeled Raji targets + Rituximab (10 ug/ml) and cells were imaged every 30 minutes...(N=4) Conclusions These results indicate that NK cells who enter the solid TME are fundamentally different than those in the bone marrow or the blood stream. Overall, the insights gained from these experiments can help overcome hypoxia induced immune suppression in the tumor microenvironment and improve NK cell-based immunotherapy for solid tumors.
  • ||||||||||  APVO603 / Medexus
    [VIRTUAL] Dual-targeting of 4-1BB and OX40 with an ADAPTIR™ bispecific antibody enhances anti-tumor responses to solid tumor () -  Oct 14, 2020 - Abstract #SITC2020SITC_1658;    
    Conclusions APVO603 is a dual-agonistic bispecific antibody that augments the effector function of activated CD4+ and CD8+ T and NK cells in a dose-dependent manner, and reduces growth of established tumors in vivo. This preclinical data, demonstrates conditional dual stimulation of 4-1BB and OX40 and supports further development of APVO603, a promising immuno-oncology therapeutic with potential for benefit in solid tumors.
  • ||||||||||  TG 100-115 / Sanofi
    [VIRTUAL] Pancreatic cancer therapy based on combination of DNA vaccination and PI3Kgamma inhibition () -  Oct 14, 2020 - Abstract #SITC2020SITC_1500;    
    Conclusions Treatment with ENO1 plus TG100-115 is able to reduce tumor size in pancreas, increase immune cell infiltration and modulate stroma cell compartment, making the therapy a suitable approach for PDA treatment. Ethics Approval All animal experiments were approved by the University of Torino, Italian Ministry of Health and performed in accordance with EU laws in the animal facility of the Molecular Biotechnology Center (MBC).
  • ||||||||||  Hyleukin-7 (efineptakin alfa) - Genexine, NeoImmuneTech, I / Mab
    [VIRTUAL] Combination of rhIL-7-hyFc and anti-PD-L1xCD3ε bispecific antibody enhances antitumor response in mice () -  Oct 14, 2020 - Abstract #SITC2020SITC_1480;    
    Our results serve as a proof-of-concept that the combination of rhIL-7-hyFc, a strong T cell amplifier, with bsAb, a tumor-targeted T-cell stimulator, would be a promising strategy for cancer immunotherapy. Ethics Approval This study was approved by POSTECH institutional animal care and use committee; approval number POSTECH-2020-0057.
  • ||||||||||  ALKS 4230 / Alkermes, Keytruda (pembrolizumab) / Merck (MSD)
    [VIRTUAL] Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial () -  Oct 14, 2020 - Abstract #SITC2020SITC_1379;    
    P1/2
    An increase in CD3+CD8+ T cells (A, red = CD3; blue = CD8; purple = CD3+CD8+; teal = tumor marker), GranzymeB (B, red = CD8; green = granzymeB; yellow = granzymeB+CD8+; teal = tumor marker), and PD-L1 (C, red = PD-L1; blue = tumor marker) in the tumor microenvironment of a single patient was observed after the patient received monotherapy ALKS 4230 Conclusions The combination of ALKS 4230, an investigational agent, and pembrolizumab demonstrates an acceptable safety profile and provides some evidence of tumor shrinkage and disease stabilization in some patients with heavily pretreated OC. This regimen could represent a new therapeutic option for these patients.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    [VIRTUAL] Enhanced immune responses in human breast and colon cancer following checkpoint therapy in a CD34+ stem cell humanized NCG (HuCD34NCG) mouse model () -  Oct 14, 2020 - Abstract #SITC2020SITC_1235;    
    Mice were randomized into treatment groups based on tumor size, and checkpoint inhibitor antibodies were dosed twice weekly (anti-human PD-1, BioXcell clone: RMP1-14 or Keytruda; anti-human CTLA-4, BioXcell clone: BN13; and combination therapy)...These results demonstrate that HuCD34NCG are a robust and relevant host for various human cell xenotransplants to advance preclinical immuno-oncology drug development. Ethics Approval Animal studies were executed in compliance with local Charles River IACUC guidelines, IACUC number I-033.
  • ||||||||||  [VIRTUAL] Myeloid Cell Infiltration Correlates with Prognosis and Varies Based on Tumor Location in Cholangiocarcinoma () -  Oct 14, 2020 - Abstract #SITC2020SITC_1036;    
    D-ECC has a favorable immune profile compared to ICC and H-ECC, with a better milieu for antigen presentation including increased mesothelin and less suppressive macrophages, which may support better response to checkpoint blockade. The data supported the hypothesis that higher densities of intra-tumoral M2 macrophages and myeloid cells correlated with worse OS, even after controlling for clinical variables, suggesting that these cell populations may represent promising immunotherapeutic targets in CC.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Oxygen concentration alters Natural Killer cell phenotype and function in the solid tumor microenvironment () -  Oct 14, 2020 - Abstract #SITC2020SITC_963;    
    At the end of the incubation period NK cells were counted and plated at a 2:1 E:T ratio with fluorescently labeled K562 targets or fluorescently labeled labeled Raji targets + Rituximab (10 ug/ml) and cells were imaged every 30 minutes...(N=4) Conclusions These results indicate that NK cells who enter the solid TME are fundamentally different than those in the bone marrow or the blood stream. Overall, the insights gained from these experiments can help overcome hypoxia induced immune suppression in the tumor microenvironment and improve NK cell-based immunotherapy for solid tumors.
  • ||||||||||  APVO603 / Medexus
    [VIRTUAL] Dual-targeting of 4-1BB and OX40 with an ADAPTIR™ bispecific antibody enhances anti-tumor responses to solid tumor () -  Oct 14, 2020 - Abstract #SITC2020SITC_923;    
    Conclusions APVO603 is a dual-agonistic bispecific antibody that augments the effector function of activated CD4+ and CD8+ T and NK cells in a dose-dependent manner, and reduces growth of established tumors in vivo. This preclinical data, demonstrates conditional dual stimulation of 4-1BB and OX40 and supports further development of APVO603, a promising immuno-oncology therapeutic with potential for benefit in solid tumors.
  • ||||||||||  TG 100-115 / Sanofi
    [VIRTUAL] Pancreatic cancer therapy based on combination of DNA vaccination and PI3Kgamma inhibition () -  Oct 14, 2020 - Abstract #SITC2020SITC_765;    
    Conclusions Treatment with ENO1 plus TG100-115 is able to reduce tumor size in pancreas, increase immune cell infiltration and modulate stroma cell compartment, making the therapy a suitable approach for PDA treatment. Ethics Approval All animal experiments were approved by the University of Torino, Italian Ministry of Health and performed in accordance with EU laws in the animal facility of the Molecular Biotechnology Center (MBC).
  • ||||||||||  Hyleukin-7 (efineptakin alfa) - Genexine, NeoImmuneTech, I / Mab
    [VIRTUAL] Combination of rhIL-7-hyFc and anti-PD-L1xCD3ε bispecific antibody enhances antitumor response in mice () -  Oct 14, 2020 - Abstract #SITC2020SITC_745;    
    Our results serve as a proof-of-concept that the combination of rhIL-7-hyFc, a strong T cell amplifier, with bsAb, a tumor-targeted T-cell stimulator, would be a promising strategy for cancer immunotherapy. Ethics Approval This study was approved by POSTECH institutional animal care and use committee; approval number POSTECH-2020-0057.